Share on

Global Migraine Drugs Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment (Preventive & Absorptive), Therapeutic Class (Triptants, Ergots & Others) & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 3948
Pages: 186
Formats: report pdf report excel report power bi report ppt

Global Migraine Drugs Market Size (2022 to 2027)

The global migraine drugs market size is projected to value USD 5.63 billion by 2027 and USD 4.44 billion in 2022, growing at a CAGR of 4.87% during the forecast period.

Migraine is a typical headache that occurs due to both nerves and blood vessels' involvement, mostly seen more in women than in men. There are two kinds of medications used to treat migraines, in which some are for the cure, and others are for prevention.

Drugs that cure migraine:

  • Anticonvulsants (Topiramate)
  • Beta-Blockers (Propranolol)
  • Antihistamine (Cyproheptadine)
  • Botulinum Toxin
  • Histamine Calcium Channel Blockers (Verapamil)

According to the Migraine Research Foundation, migraine ranked as the 3rd most prevalent illness and 6th most disabling illness worldwide. Around 39 million in the United States and over 1 billion population is now suffering from migraine.

According to Medline article, nearly 12% of the U.S. population suffers from migraine headaches. The treatment of this migraine headache is treatable by using preventive medications. For Instance, a device known as the Cefaly Transcutaneous Electrical Nerve Stimulating device is approved by the FDA to treat migraines. This device increases the trigeminal nerve by emitting electric currents and provides temporary pain from a migraine.

MARKET DRIVERS:

Y-O-Y growth in the incidence of migraine among people, the rising population worldwide, and the growing demand for quality drugs are significant factors driving the growth of the global migraine drugs market. The incidence of migraines is higher in women than in men. Therefore, the growing female population worldwide is a big plus to the global migraine drugs market expansion.

Additionally, factors such as increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients associated with the prevention and treatment of migraine further increase the demand levels for the global migraine drugs market. Furthermore, rising pharmaceutical R&D expenditures, increasing healthcare spending, and a high prevalence of migraines are expected to boost the growth rate of the global migraine drugs market during the forecast period.

Creating awareness over the availability of different treatment procedures for migraines in rural areas boosts the market demand. Investments in the development of new drugs by market players and other companies also level up the market's growth rate. In addition, changes in lifestyles and rising stress levels among people are factors for the market to grow.

MARKET RESTRAINTS: 

Side effects that connect with migraine drugs are hampering the growth of the market. In addition, stringent rules and regulations by the government are also hindering the growth rate of the migraine drugs market. Also, drugs' harmful effects and the increasing precedence of other therapies restrain the growth during the period.

Impact of COVID-19 on the global migraine drugs market:

Migraine is one of the medical conditions of headache. Many COVID-19 patients who had recovered have reported that they felt a headache-like migraine during the quarantine period. The sudden outbreak of COVID-19 has increased stress levels in a considerable amount of the world globally, thus reflected in the global increase of people suffering from migraines. The market for migraine drugs has seen a spike in demand since the beginning of the COVID-19 pandemic. Regions such as North America, Europe, and APAC had registered significant growth in 2020. In addition, increased retail sales of triptans demanded by people with acute migraine conditions have accelerated the market to grow substantially. Analysts at Market Data Forecast have predicted that, with the support received from COVID-19, the global migraine drugs market will register new growth heights during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Analysed

By Treatment, Therapeutic class, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global migraine drugs market has been segmented and sub-segmented based on treatment, therapeutic class, and region.

Migraine Drugs Market - By Treatment:

  • Preventive
  • Absorptive

Based on the treatment type, the preventive segment is likely to hold the most substantial market share during the forecast period due to the increasing knowledge of the therapies.

Migraine Drugs Market - By Therapeutic Class:

  • Triptants
  • Ergots
  • Others

Based on the therapeutics, the triptans segment is predicted to account for a considerable share in the global migraine drugs market from 2021 to 2026. Escalating expenditure on healthcare is undoubtedly to push the demand for this category.

Migraine Drugs Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Geographically, the North American market is likely to dominate the global migraine drugs market growth due to several people suffering from headaches.

Asia-Pacific Market expects to have a high CAGR from 2020 to 2025 due to the successful initiatives taken by the governments of Asia Pacific countries to bring awareness towards migraines. In this region, India and China are the countries that contribute to the migraine drugs market.

In Europe and LAMEA regions, there is an increase in research and development activities, which is likely to surge up the market growth. Asia-Pacific to have substantial growth in the upcoming years.

KEY MARKET PARTICIPANTS:

Companies playing a promising role in the global migraine drugs market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories, Abbott, Aeriel BioPharma, Alder Biopharmaceuticals, Bayer, CoLucid, Eli Lilly, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, and Winston Pharmaceuticals.

RECENT MARKET DEVELOPMENTS:

  • In December 2019, Ubrelvy received FDA approval for Allergan, a new oral medication for migraine sufferers. This medicine is very effective in treating the migraine where the patient is unresponsive for other treatment procedures.
  • In January 2020, Eli Lilly launched a new medicine to treat migraines named Reyvow, and the FDA has approved. It is the first drug to treat pain and the sensitivity of light, sound, and nausea.
  • In September 2018, Teva’s Ajovy became the second CGRP medicine, which the US FDA has approved. In addition, Ajovy is the first and the only CGRP antibody that offers patients quarterly and monthly dosages.
  • In the same year, Eli Lilly and Company has received the US FDA acceptance for the approval of Emgality, a 120mg injection for the medicinal treatment of migraine only in adults.
  • Allergan’s Botox, a neurotoxin, is used as a preventive measure for the migraine market. It is the only drug that had the approval to apply for prevention. However, botox is likely to face competition from the launch of Amgen/Novartis that targets both chronic and separate parts that are having a migraine.
  • In May 2018, Aimovig was approved by the US FDA, which is a drug that helps treat chronic migraines. It is the first new class of migraine treatments called CGRP antagonists.
  • AOBiome therapy lpsis developed as a novel antibacterial agent AOB-203 for the prevention of migraine. The product is an ammonia-oxidizing bacteria AOB, which produces nitric oxide that regulates the swollen parts and dilates blood vessels that decrease blood pressure related to migraines.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample